OIG study supports adequacy of ASP payments for cancer drugs, CMS says

Article Overview

This article covers a government assessment of Medicare reimbursement for cancer-related drugs under the ASP-based payment system, along with reactions from CMS and ASCO. It is relevant to professionals who follow oncology drug payment policy, Medicare reimbursement methodology, and practice-level cost concerns for physician offices that buy and administer these drugs. The article focuses on the scope of the review, the specialties included, and the general findings and responses reported by the organizations involved.